129 related articles for article (PubMed ID: 36813175)
1. Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE.
Vendrely V; Lemanski C; Pommier P; LE Malicot K; Saint A; Rivin Del Campo E; Regnault P; Baba-Hamed N; Ronchin P; Crehange G; Tougeron D; Menager-Tabourel E; Diaz O; Hummelsberger M; Minsat M; Drouet F; Larrouy A; Peiffert D; Lievre A; Zasadny X; Hautefeuille V; Mornex F; Lepage C; Quero L;
Radiother Oncol; 2023 Jun; 183():109542. PubMed ID: 36813175
[TBL] [Abstract][Full Text] [Related]
2. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
[TBL] [Abstract][Full Text] [Related]
3. Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.
Gouriou C; Lemanski C; Pommier P; Le Malicot K; Saint A; Rivin Del Campo E; Evin C; Quero L; Regnault P; Baba-Hamed N; Ronchin P; Crehange G; Tougeron D; Menager-Tabourel E; Diaz O; Hummelsberger M; de la Rocherfordiere A; Drouet F; Vendrely V; Lièvre A
Br J Cancer; 2024 Mar; 130(5):769-776. PubMed ID: 38184691
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
5. Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial.
Vendrely V; Ronchin P; Minsat M; Le Malicot K; Lemanski C; Mirabel X; Etienne PL; Lièvre A; Darut-Jouve A; de la Fouchardière C; Giraud N; Breysacher G; Argo-Leignel D; Thimonnier E; Magné N; Abdelghani MB; Lepage C; Aparicio T;
Radiother Oncol; 2023 Sep; 186():109742. PubMed ID: 37315583
[TBL] [Abstract][Full Text] [Related]
6. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial).
Murofushi KN; Itasaka S; Shimokawa M; Murakami Y; Yamamoto T; Nishimura Y; Kudo S; Sakamoto T; Ariga T; Ogo E; Taguchi K; Jingu K; Ogawa K
J Radiat Res; 2023 Jan; 64(1):154-161. PubMed ID: 36280895
[TBL] [Abstract][Full Text] [Related]
9. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
Holliday EB; Morris VK; Johnson B; Eng C; Ludmir EB; Das P; Minsky BD; Taniguchi C; Smith GL; Koay EJ; Koong AC; Delclos ME; Skibber JM; Rodriguez-Bigas MA; You YN; Bednarski BK; Tillman MM; Chang GJ; Jennings K; Messick CA
Oncologist; 2022 Feb; 27(1):40-47. PubMed ID: 35305097
[TBL] [Abstract][Full Text] [Related]
10. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure.
de Meric de Bellefon M; Lemanski C; Castan F; Samalin E; Mazard T; Lenglet A; Demontoy S; Riou O; Llacer-Moscardo C; Fenoglietto P; Aillères N; Thezenas S; Debrigode C; Vieillot S; Gourgou S; Azria D
Radiother Oncol; 2020 Mar; 144():141-147. PubMed ID: 31809980
[TBL] [Abstract][Full Text] [Related]
12. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
[TBL] [Abstract][Full Text] [Related]
14. Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis.
Neelis KJ; Kip DM; Speetjens FM; van der Linden YM
Radiat Oncol; 2022 Apr; 17(1):81. PubMed ID: 35443730
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005).
Gul SK; Tepetam H; Yildiz F; Er I; Oksuz DC; Parvizi M; Ozden AS; Alicikus ZA; Sari SY; Alomari O; Gorken IB
Clin Colorectal Cancer; 2023 Sep; 22(3):318-326. PubMed ID: 37336706
[TBL] [Abstract][Full Text] [Related]
16. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
17. What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort.
Bacci M; Quero L; Barbier E; Parrot L; Juguet F; Pommier P; Bazire L; Etienney I; Baba-Hamed N; Spindler L; François E; Ronchin P; Campo ERD; Lemanski C; Lièvre A; Siproudhis L; Abramowitz L; Lepage C; Vendrely V
Dig Liver Dis; 2021 Jun; 53(6):776-784. PubMed ID: 33867291
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer.
Leiker AJ; Wang CJ; Sanford NN; Aguilera TA; Karri S; Beg MS; Kazmi SA; Olson C; Matthews JA; Abdelnaby A; Meyer JJ; Folkert MR
Am J Clin Oncol; 2020 Oct; 43(10):701-708. PubMed ID: 32694298
[TBL] [Abstract][Full Text] [Related]
19. Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma.
Untiedt S; Rolf D; Scobioala S; Wolters H; Elsayad K; Oertel M; Kittel C; Pascher A; Rijcken E; Ullerich H; Glasbrenner B; Eich HT
Strahlenther Onkol; 2023 Aug; 199(8):749-760. PubMed ID: 36862155
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
